Strategic leverage Aphios operates in green enabling biotechnology and nanotechnology drug delivery with a focus on biologics safety, cancer, infectious diseases and CNS disorders. This presents opportunities to partner with contract development and manufacturing organizations (CDMOs), pharmaceutical developers, and research institutions seeking advanced, safer delivery platforms and viral safety improvements.

Vaccine & stability Recent news highlights room temperature stable single-shot mRNA vaccine and double nanoencapsulation in lipid nanoparticles, signaling a capability to address cold-chain challenges and dosing optimization. Target buyers include public health agencies, vaccine manufacturers, and biotech firms seeking stable mRNA platforms and scalable delivery solutions.

Niche CNS pipeline Development of Bryoids for CNS diseases such as Alzheimer's, MS and glaucoma indicates a specialized portfolio for neurology-focused partners and grant opportunities. Explore collaborations with academic centers, biotech firms, and pharma companies pursuing advanced CNS therapeutics and neurodegenerative disease programs.

Grant-funded potential Active NIH SBIR work on opioid use disorder relapse therapies suggests readiness for government-funded collaborations and milestone-driven programs. Pursue co-development deals with drug developers targeting addiction treatment, as well as continuation funding from public sources to de-risk early-stage projects.

KB & boutique scale Smaller, 11-50 employee biotech with revenue in the low millions positions Aphios as an agile partner for late-stage development support, regulatory bridging, and contract research or manufacturing services. Ideal targets include mid-sized biotech firms and niche players seeking specialized delivery technologies without the overhead of large CROs.